Key facts
- This page summarizes Bruce Booth's Form 4 filing for Kymera Therapeutics, Inc. (KYMR).
- 31 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 22 Jun 2026, 21:01.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Sale
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Additional SEC filing notes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2025.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.95 to $90.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2), (4) and (7) through (19).
Footnote F3
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.05 to $91.03 inclusive.
Footnote F5
These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
Footnote F6
The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.
Footnote F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.05 to $91.04 inclusive.
Footnote F8
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.10 to $92.085 inclusive.
Footnote F9
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.1191 to $92.2833 inclusive.
Footnote F10
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.11 to $92.50 inclusive.
Footnote F11
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.93 to $94.91 inclusive.
Footnote F12
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.99 to $95.76 inclusive.
Footnote F13
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.00 to $96.959 inclusive.
Footnote F14
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.0018 to $97.99 inclusive.
Footnote F15
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.00 to $98.9997 inclusive.
Footnote F16
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.00 to $99.9942 inclusive.
Footnote F17
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.8925 inclusive.
Footnote F18
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.00 to $101.98 inclusive.
Footnote F19
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.01 to $103.00 inclusive.
Footnote F20
Fully vested and exercisable.
SEC remarks
Due to the 30 line limitation in Table I, this report is being filed across two forms. This is the first of two filings.